Senti Biosciences (SNTI) Competitors $3.32 +0.15 (+4.73%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI vs. PGEN, MAZE, PRTC, ABVX, AUTL, ETON, RVNC, RAPP, AMLX, and KMDAShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Precigen (PGEN), Maze Therapeutics (MAZE), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), Autolus Therapeutics (AUTL), Eton Pharmaceuticals (ETON), Revance Therapeutics (RVNC), Rapport Therapeutics (RAPP), Amylyx Pharmaceuticals (AMLX), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Precigen Maze Therapeutics PureTech Health ABIVAX Société Anonyme Autolus Therapeutics Eton Pharmaceuticals Revance Therapeutics Rapport Therapeutics Amylyx Pharmaceuticals Kamada Precigen (NASDAQ:PGEN) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Which has higher valuation and earnings, PGEN or SNTI? Senti Biosciences has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$3.93M116.87-$95.90M-$0.48-3.25Senti Biosciences$2.56M33.72-$71.06M-$12.03-0.28 Does the MarketBeat Community prefer PGEN or SNTI? Precigen received 433 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 67.44% of users gave Precigen an outperform vote while only 40.00% of users gave Senti Biosciences an outperform vote. CompanyUnderperformOutperformPrecigenOutperform Votes43767.44% Underperform Votes21132.56% Senti BiosciencesOutperform Votes440.00% Underperform Votes660.00% Do analysts prefer PGEN or SNTI? Precigen currently has a consensus target price of $7.00, indicating a potential upside of 348.72%. Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 201.20%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Senti Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor PGEN or SNTI? In the previous week, Senti Biosciences had 7 more articles in the media than Precigen. MarketBeat recorded 8 mentions for Senti Biosciences and 1 mentions for Precigen. Precigen's average media sentiment score of 1.72 beat Senti Biosciences' score of 0.37 indicating that Precigen is being referred to more favorably in the media. Company Overall Sentiment Precigen Very Positive Senti Biosciences Neutral Which has more risk and volatility, PGEN or SNTI? Precigen has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.32, indicating that its stock price is 132% more volatile than the S&P 500. Is PGEN or SNTI more profitable? Senti Biosciences has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Precigen's return on equity of -123.06% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Precigen-3,521.68% -123.06% -87.33% Senti Biosciences N/A -154.84%-77.42% Do institutionals & insiders hold more shares of PGEN or SNTI? 33.5% of Precigen shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 44.9% of Precigen shares are held by company insiders. Comparatively, 10.7% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryPrecigen beats Senti Biosciences on 11 of the 17 factors compared between the two stocks. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.33M$3.00B$5.57B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.2130.4222.4218.48Price / Sales33.72498.92394.10103.91Price / CashN/A168.6838.1834.62Price / Book0.223.206.774.25Net Income-$71.06M-$72.35M$3.22B$248.23M7 Day Performance-25.06%3.57%3.26%3.29%1 Month Performance-3.21%0.17%0.02%2.42%1 Year Performance-7.78%-21.21%18.01%5.54% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences2.8564 of 5 stars$3.32+4.7%$10.00+201.2%+2.4%$86.33M$2.56M-0.214News CoverageGap UpPGENPrecigen3.6507 of 5 stars$1.37-1.4%$7.00+410.9%+10.0%$408.72M$3.93M-2.49190News CoverageMAZEMaze TherapeuticsN/A$9.13+8.6%$25.67+181.1%N/A$399.86M$167.50M0.00121PRTCPureTech Health2.3346 of 5 stars$16.64-0.6%$45.00+170.5%-38.6%$399.56M$3.33M0.00100Gap DownABVXABIVAX Société Anonyme2.2184 of 5 stars$6.23-2.7%$38.00+510.0%-54.1%$395.10MN/A0.0061Analyst ForecastNews CoverageGap UpAUTLAutolus Therapeutics2.6929 of 5 stars$1.44+0.7%$9.32+547.2%-65.5%$383.18M$10.12M-1.19330News CoverageGap UpETONEton Pharmaceuticals2.3421 of 5 stars$14.26-0.6%$27.67+94.0%+368.5%$382.43M$39.01M-64.8220Analyst RevisionNews CoverageRVNCRevance Therapeutics2.0971 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Upcoming EarningsAnalyst ForecastRAPPRapport Therapeutics2.4387 of 5 stars$10.38+2.3%$32.67+214.7%N/A$378.83MN/A-0.75N/ANews CoverageAMLXAmylyx Pharmaceuticals3.0241 of 5 stars$4.23+6.3%$8.00+89.1%+157.9%$374.79M$87.37M-1.11200Positive NewsKMDAKamada3.8653 of 5 stars$6.40-1.5%$14.67+129.2%+25.0%$373.62M$160.95M22.86360Upcoming EarningsShort Interest ↓Positive News Related Companies and Tools Related Companies Precigen Alternatives Maze Therapeutics Alternatives PureTech Health Alternatives ABIVAX Société Anonyme Alternatives Autolus Therapeutics Alternatives Eton Pharmaceuticals Alternatives Revance Therapeutics Alternatives Rapport Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Kamada Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNTI) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNTI Stock Free SNTI Stock Alerts